Skip to main content
. 2016 Aug 25;7(40):65643–65659. doi: 10.18632/oncotarget.11595

Figure 4. Effects of HL156A, TMZ, and combination treatment on stemness and neuroglial differentiation of GBM-TSs.

Figure 4

A, B. Effects of HL156A and combination treatment with HL156A and TMZ on stemness were assessed using tumorsphere-formation assays (A) and quantified (B), revealing a decrease in the number of neurospheres. C. Cytotoxicity during tumorsphere-formation assays was minimal, as evidenced by the results of LDH assays. D. Combination treatment with HL156A and TMZ decreased expression of the stemness markers Oct3/4, Sox2, and Notch2.